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Introduction: Cholangiocarcinoma (CCA) is an aggressive disease with limited effective treatment options. The
PI3K/Akt/mTOR pathway represents an attractive therapeutic target due to its frequent dysregulation in CCA.
MK2206, an allosteric Akt inhibitor, has been shown to reduce cellular proliferation in other cancers. We hypothesized
that MK2206 mediated inhibition of Akt would impact CCA cellular viability.
Study methods: Post treatment with MK2206 (0-2 μM), cellular viability was assessed in two human CCA cell
lines—CCLP-1 and SG231—using an MTT assay. Lysates from the MK2206 treated CCA cells were then examined
for apoptotic marker expression levels using Western blot analysis. Additionally, the effect on cellular proliferation
of MK2206 treatment on survivin depleted cells was determined.
Results: CCLP-1 and SG231 viability was significantly reduced at MK2206 concentrations of 0.5, 1, and 2 μM by
approximately 44%, 53%, and 64% (CCLP-1; p = 0.01) and 32%, 32%, and 42% (SG231; p < 0.00005) respectively.
Western analysis revealed a decrease in AKTSer473, while AKTThr308 expression was unchanged. In addition, cleaved
PARP as well as survivin expression increased while pro-caspase 3 and 9 levels decreased with treatment. Depletion of
survivin in CCLP-1 cells resulted in apoptosis as evidenced by increased cleaved PARP. In addition, survivin siRNA
further enhanced the antitumor activity of MK2206.
Conclusions: This study demonstrates that by blocking phosphorylation of Akt at serine473, CCA cellular growth
is reduced. The growth suppression appears to be mediated via apoptosis. Importantly, combination of survivin
siRNA transfection and MK2206 treatment significantly decreased cell viability.
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Cholangiocarcinoma (CCA) is a rare but aggressive
malignancy arising from the epithelium of either the
intrahepatic (ICC) or extrahepatic (ECC) biliary ducts
[1,2]. While cholangiocarcinoma represents only 3% of
all gastrointestinal malignancies, it is the second most
common primary hepatic lesion trailing only hepato-
cellular carcinoma (HCC) [1-3]. Despite its rarity, inci-
dence of intrahepatic CCA has been rising internationally
and it has overtaken HCC as the most lethal primary liver
cancer in England and Whales [4,5].* Correspondence: mkunnima@mcw.edu; tcgamblin@mcw.edu
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unless otherwise stated.Currently, surgical resection offers the only curative
treatment for CCA [1,3,4]. However, the majority of
patients present with unresectable disease and even in
those achieving a R0 resection, 5-year survival rates
remain low (22-35% [3,4,6-8]) with greater than 50%
recurrence at a median 31-month follow-up [8]. In
unresectable cases, transarterial chemoembolization
(TACE) (gemcitabine with cisplatin or oxaliplatin) has
been shown to improve survival but only to a median
survival of approximately 14 months [9]. Liver trans-
plantation in unresectable cases is another option in
highly selected patients, but is limited due to scarcity
of donors [3,10]. Overall, the median survival without
treatment is reported to be only 5–8 months, with
5-year survival at <5% [1,9,11]. Therefore, because theThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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has demonstrated substantial efficacy [9], there exists
an urgent need for identification of novel therapeutic
targets.
The phosphatidylinositol 3-kinase (PI3K)/protein kinase
B (Akt)/mTOR pathway is an attractive therapeutic target
as it is involved in cellular survival, proliferation, metas-
tasis, metabolism, and angiogenesis [11-14]. The dys-
regulation of this pathway has been implicated in the
pathogenesis of many cancer types, including CCA
[11-15]. Studies have demonstrated that increased ex-
pression of phosphorylated Akt is present in >80% of
extrahepatic CCA [12] and >60% of intrahepatic CCA
[13,16]. Therefore, inhibition of this pathway could
prove therapeutic.
MK2206, a novel, small molecule, allosteric Akt inhibi-
tor has demonstrated promising efficacy in vitro and in
early clinical trial [11,15,17,18]. While several Akt inhibi-
tors have been developed, many have been plagued by
either non-specificity, unacceptable toxicities, or have
lacked anti-tumor efficacy in vivo [19]. Thus far, MK2206
has demonstrated moderate single agent anti-tumor effi-
cacy with acceptable toxicity in humans [17]. Despite one
previous report of MK2206 use in cholangiocarcinoma,
the mechanism of action in these cells needs significant
clarification [11].
This study sought to examine the effects of MK2206
on two human CCA cell lines—CCLP-1 and SG231. The
effects of MK2206 on CCA cellular proliferation were
examined and the mechanism of cellular growth inhib-
ition was identified by Western blot analysis. By inhibiting
Akt phosphorylation via MK2206, it was hypothesized that
CCA cellular proliferation would be reduced via induction
of apoptosis.Materials and methods
Cell culture and treatment
CCLP-1 and SG231 are human, intrahepatic cholangio-
carcinoma cell lines (courtesy of Dr. Anthony J. Demetris,
University of Pittsburgh, Pittsburgh, PA). CCLP-1 cells
were maintained in Dulbecco Modified Eagle Medium
(Sigma-Aldrich, St. Louis, Missouri, USA) supplemented
with 10 mM HEPES (Life Technologies, Grand Island,
New York, USA), 100 IU/ml penicillin, 100 μg/ml strepto-
mycin (Life Technologies), 1× non-essential amino acids
(Life Technologies), and 10% Fetal Bovine Serum (Life
Technologies). SG231 cells were maintained in Minimal
Essential Medium Alpha Medium (Life Technologies)
supplemented with 10% Fetal Bovine Serum (Life
Technologies). Both cell lines were grown in a humidified
incubator at 37°C and 5% CO2. MK2206 was dissolved in
dimethyl sulfoxide (DMSO; Sigma-Aldrich). Cells were
then treated with varying concentrations of MK2206.Cellular viability
CCLP-1 and SG231 cellular viability was determined
using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (MTT; Sigma-Aldrich) colorimetric assay.
CCLP-1 and SG231 cells were plated in 24-well plates
and left overnight to adhere. Cells were then treated at
indicated concentrations of MK2206 in quadruplicates.
Cell media with corresponding MK2206 concentrations
was replenished at the 48 hour time interval. At 96 hours,
media was replaced with 250 μL of RPMI media (Life
Technologies) containing 0.5 mg/ml MTT. The cells were
then incubated for 3.5 hours at which point 750 μl DMSO
was added to each well. After another 5-minute incuba-
tion, absorbance was measured at 540 nm using a spectro-
photometer (TECAN Infinite M200 PRO, San Jose, CA).
Small Interfering RNA transfection
For the siRNA transfection, CCLP-1 cells were plated
into either 60 mm or 100 mm plates and allowed to
grow over night. Then the cells were transiently trans-
fected with non-specific, no target, control siRNA or
survivin siRNA for 48 hours using Lipofectamine (Invi-
trogen, Carlsbad, CA, USA). The cells were subsequently
prepared for use in further experiments. For the cell
proliferation assay, the siRNA transfected cells from
100 mm plates were collected, counted and plated on a
48 well plate in quadruplicates. The following day, the
cells were treated with DMSO (control) or MK2206 (0.5
and 1 μM) for an additional 48 hours. Cellular viability
was measured as described above.
Western blot analysis
After treatment with varying concentrations of MK2206
for 96 hours, CCA cells were lysed in RIPA buffer(Thermo
Fisher) [15,20]. The total cellular protein concentrations
were then quantified using a bicinchoninic acid (BCA)
assay (Pierce, Rockford, Illinois, USA). After quantifica-
tion, 30 μg of denatured protein was loaded onto 7.5,
10, 12, or 4-15% SDS-PAGE gels (Bio-Rad Laboratories,
Hercules, CA, USA). The protein was then transferred
to a nitrocellulose membrane (Bio-Rad) using a Trans-
Blot Turbo (Bio-Rad). The membranes were subsequently
blocked in PBS-T containing milk (1× PBS, 5% dry milk,
0.05% Tween-20) for 30–60 minutes. The blocked mem-
branes were then incubated overnight at 4°C in their
respective primary antibodies. The antibodies were di-
luted as follows: phosphorylated-AktSer473, total-PARP,
cleaved PARP, (1:1000; Cell Signaling Technology,
Beverly, Massachusetts, USA), cyclin D1, survivin and
total Akt (Santa Cruz Biotechnology, Santa Cruz, CA,
USA) were diluted 1:1000, 1:500, and 1:2000 respectively.
Caspase-3, Caspase-9, and phosphorylated-AktThr308
(Cell Signaling Technology) were diluted 1:1000. In
addition, glyceraldehyde-3-phosphate dehydrogenase
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After overnight incubation in primary antibody, mem-
branes were then washed 3 times for 5 minutes with
PBS-T wash buffer (1 × PBS, 0.05% Tween 20). Mem-
branes where then incubated for one hour in either
anti-rabbit or anti-mouse secondary antibody (Santa
Cruz Biotechnology; 1: 4000 dilution) depending on the
source of the primary antibody. Following incubation,
membranes were washed 3 times for 5 minutes each time
in PBS-T wash buffer and then developed using Super-
Signal West Dura, Femto (Thermo Scientific, Waltham,
MA, USA), Immunstar, or Clarity (Bio-Rad) kits. Molecu-
lar Images ChemiDoc XRS+ imager with image lab soft-
ware (Bio-Rad) was used to visualize the intensity of
bands according to manufacturer’s instructions. Follow-
ing development, band intensities were quantified using
ImageJ software (NIH, Bethesda, USA) as needed.
Statistical analysis
Unless otherwise noted, all results represent mean ± SEM.
Significance between treatments was determined using
SPSS statistics software (International Business Machines
Coporation (IBM), Armonk, New York, USA; Oneway
ANOVA). P-values of less than 0.05 were considered
significant.
Results
MK2206 treatment reduces Cholangiocarcinoma cellular
proliferation in a dose and time dependent manner
Cell viability results, as measured by MTT assay, indi-
cated a dose and time correlate for growth reduction in
both the CCLP-1 and SG231cell lines (Figure 1). After
48 hours, CCLP-1 and SG231 viability was reduced on
average by 39% and 27% respectively (DMSO v. 2 μM;
p < 0.0005 and p = 0.001 respectively). At 96 hours,Figure 1 Dose-dependent growth reduction upon MK2206 treatment
treatment with MK2206 at the indicated doses. Growth reduction was signCCLP-1 viability was significantly reduced at MK2206
concentrations of 0.5, 1, and 2 μM by approximately
44%, 53%, and 64% respectively (p = 0.01). SG231 also
demonstrated significant reduction in viability of 32%,
32%, and 42% respectively for the same treatment con-
centrations (p < 0.0005) (Figure 2).
MK2206 reduces levels of phosphorylated AktSer473 in
CCLP-1 and SG231 cells
In order to confirm MK2206’s mechanism of action and
the previously reported specificity [21], levels of AktSer473,
AktThr308, and total Akt expression were examined by
Western blot analysis. In both CCLP-1 and SG231 cell
lines, AktSer473 was significantly reduced in MK2206
treated cells (0.1-2 μM; Figure 2). Quantification of the
intensity of bands revealed a dose dependent reduction
in expression of AktSer473 in both cell lines with a plat-
eau between 0.5-1 μM MK2206 treatment levels in
CCLP-1 (Figure 3A, B). Ultimately, treatment resulted
in a reduction in levels of AktSer473 by >95% in both cell
lines (DMSO v. 2 μM MK2206) whereas expression
levels of AktThr308, the other phosphorylation site for
Akt activation, were not changed by MK2206 treatment.
Additionally, treatment did not affect the level of total
Akt expression in cells, confirming the mechanism of
MK2206 action to be specific inhibition of AktSer473
phosphorylation (Figure 2).
Apoptosis induction accounts for the reduction in cellular
proliferation upon MK2206 treatment
Western blot analysis was used to examine expression
levels of full-length PARP, cleaved PARP, Caspase 3 and 9,
and survivin in order to determine the effect of Akt inhib-
ition on CCA. In CCLP-1, while full-length PARP expres-
sion was not noticeably different upon Akt inhibition,. MTT assay was used to determine cellular viability after 96 hours of
ificant in both cell lines at 0.5, 1, and 2 μM (p < 0.05).
Figure 2 MK2206 specifically inhibits phosphorylation at Serine 473 in CCA cells, leading to induction of apoptosis. After 96 hours of
MK2206 treatment at the indicated doses, CCLP-1 and SG231 cells were lysed and Western blot analysis was used to determine expression levels
of phosphorylated AKT and total AKT in addition to apoptotic markers (Pro-Caspase 3, Pro-Caspase 9, and Survivin).
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with expression first noted at the 0.25 μM MK2206
treatment level. However, in SG231, both full-length
and cleaved PARP were equally expressed at all treat-
ment levels (Figure 4). In both CCLP-1 and SG231, pro-
caspase 3 and 9 were reduced significantly, indicating
that drug treatment is leading to the cleavage of these
proteins and inducing an apoptotic process (Figure 2).
Interestingly, survivin, an anti-apoptotic protein was
unexpectedly up-regulated in a dose dependent manner
upon MK2206 treatment (Figure 2).
Effect of survivin siRNA transfection on cell viability in
CCLP-1
Survivin siRNA was used to determine the effect on
apoptosis in CCLP-1 cells. Survivin siRNA transfection
resulted in induction of apoptosis as evidenced by the
increased expression of cleaved PARP, cleaved caspase-3
whereas decreased expression of cyclin D1 and total
PARP proteins compared to nonspecific siRNA trans-
fected cells (Figure 5A). Importantly, survivin siRNAFigure 3 Quantification of AktSer473 western blot bands using ImageJ
Serine 473 by MK2206 is approximately dose dependent.decreased the viability of CCLP-1 cells compared to
control siRNA transfected group (Figure 5B). However,
survivin siRNA transfection combined with MK2206
treatment of 0.5 and 1 μM for 48 hours significantly
decreased cell viability (p = 0.01, compared with MK2206
alone; Figure 5B).
Discussion
Cholangiocarcinoma represents a devastating malignancy
that is plagued clinically by late detection and poor overall
prognosis. Patients are often not surgical candidates but
even with margin negative resection, most patients will ex-
perience recurrence and the prognosis is dismal [3,4,6-8].
Therefore, the majority of patients require systemic ther-
apy, but to date no available therapy has proved especially
efficacious [9]. The lack of available therapies necessitates
the identification of novel therapeutic targets. The present
study investigates the role of one such target: the PI3K/
Akt/mTOR pathway.
The PI3K/Akt/mTOR pathway plays an important role
in CCA pathogenesis as evidenced by its reported oversoftware. A) CCLP B) SG231. Inhibition of Akt phosphorylation at
Figure 4 MK2206 treatment induced cleavage of PARP in the CCLP cell line, confirming the mechanism of growth inhibition appears
to be via apoptosis induction. At the low concentrations used in this study, PARP and Cleaved PARP expression levels were not affected by
MK2206 treatment in the SG231 cell line.
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noma [12,13,16]. This, in addition to the known func-
tions of Akt and a previous report demonstrating
apoptosis induction upon Akt knockdown, indicates that
Akt inhibition could be a potential therapeutic target
[11-14,21]. Despite evidence that inhibition of all threeFigure 5 Effects of survivin siRNA transfection and combined MK2206
in apoptosis. B) Combined treatment of MK2206 in survivin siRNA transfect
non-specific (NS) siRNA plus MK2206 treatment.Akt isoforms is necessary for maximal apoptosis induc-
tion, it is thought that isoform specific inhibition may
mitigate toxicity in vivo [19,21]. Previous reports have
shown that MK2206 may have Akt isoform specificity
for Akt 1 and 2, which is consistent with the relative
tolerability of MK2206 in clinical trial [17,18].treatment on CCLP-1 cells. A) Survivin siRNA transfection resulted
ed cells showed significant reduction in cell viability compared to
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the efficacy of MK2206 as a single agent in other cancer
types or in synergistic combination with RAD001 (an
mTOR inhibitor) in cholangiocarcinoma cells in vitro.
Ewald et al. [11] demonstrated an increase in p27, a cell
cycle inhibitor, upon MK2206 treatment in two of three
CCA cell lines (EGI-1, TFK-1, and SK-ChA-1 cell lines).
While some induction of cell cycle arrest in CCA cells
upon MK2206 treatment was observed, apoptotic markers
were not fully investigated [11].
Examination of protein expression levels post-MK2206
treatment in the present study revealed that MK2206
specifically inhibits phosphorylation at AKTSer473. In
CCLP-1 and SG231 cholangiocarcinoma cell lines,
AKTThr308 and total AKT expression levels were not
affected by drug treatment, confirming drug specificity.
AKTSer473 phosphorylation inhibition occurred in a dose
dependent manner resulting in a dose dependent reduc-
tion in cellular viability at 48 and 96 hours in both cell
lines. Importantly, the concentrations needed for growth
reduction in CCA are less than those needed in other
cancer types. It is anticipated that these concentrations
could be achieved in vivo with limited toxicity.
The results of this study indicate that MK2206 is
effective in reducing CCA cellular proliferation via the
induction of apoptosis. Interestingly, survivin was up
regulated in both CCLP-1 and SG231 upon MK2206
treatment. This is an intriguing finding given survivin’s
established anti-apoptotic function. It is speculated that
compensatory activation of survivin could be mitigating
MK2206 mediated apoptosis induction. In addition, a
recent report on MK2206 use in hepatocellular carcin-
oma identified survivin as an important downstream
mediator upon MK2206 treatment, and found increased
apoptosis and reduced viability when survivin knock-
down was added to the treatment regimen [24]. Given
these findings, we used siRNA knockdown of survivin in
order to determine the role of survivin in MK2206 treat-
ment. The combination of survivin siRNA transfection
and MK2206 treatment resulted in significant reduction
in cell viability when compared to MK2206 treatment
alone. These results suggest that the inhibition of survi-
vin may sensitize the CCLP-1 cells to MK2206 treatment
by preventing the activation of pro-survival proteins.
In the present study, we have demonstrated the effect-
iveness of MK2206 in inducing apoptosis as a monother-
apy in CCA cell lines in vitro. Future work will investigate
MK2206 use in vivo and will center on developing more
effective combination therapies. Synergistic combination
treatments are particularly promising as Akt pathway acti-
vation has been shown to mitigate chemotherapy and
radiotherapy efficacy in treating CCA [25-29]. The known
chemo-resistance of CCA may be attributable, at least in
part, to Akt pathway activation [25]. Previous work hasdemonstrated enhanced sensitivity to treatment with
oxaliplatin, gemcitabine and radiotherapy upon PI3K/
mTOR/AKT inhibition and conversely, has demon-
strated increased resistance to treatment with Akt acti-
vation [25-29]. Lastly, autophagy may be playing an
important role, as PI3K/mTOR/Akt pathway inhibition
has been shown to increase autophagy in CCA cells.
Similarly, the nutritionally stressed and hypoxic micro-
environment of tumors in vivo could also lead to increased
autophagy. Importantly, inhibition of autophagy in CCA
has been shown to induce apoptosis and increase chemo-
sensitivity [30,31]. Future work should investigate the effi-
cacy of combining MK2206 with other chemotherapy
agents as well as clarifying the role of autophagy in this
process.
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